68Ga-citrate PET/MR Imaging for Glioma

Stopped early

Conditions studied: Glioma

In brief

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Key facts

Study ID

NCT03335280

Run by

Susan Chang

People needed

2

Starts

2019-02-26

Expected to finish

2020-04-24

Last updated by the study team

2020-05-01

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery
• Age >= 18 yrs.
• Karnofsky performance status of >= 60
• Ability to understand a written informed consent document, and the willingness to sign it.
• Cohort A:
• Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy
• Cohort B:
• Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

You may not qualify if…

• Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)
• Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.